Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Balazs Acs

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
The Journal of Pathology|August 30, 2019
Next generation pathology: artificial intelligence enhances histopathology practiceBalazs Acs, Johan Hartman
Breast Cancer Research and Treatment|June 24, 2020
Prognostic potential of automated Ki67 evaluation in breast cancer: different hot spot definitions versus true global scoreStephanie Robertson, Balazs Acs, Michael Lippert, et al.
Heliyon|July 18, 2024
Ensemble-based deep learning improves detection of invasive breast cancer in routine histopathology imagesLeslie Solorzano, Stephanie Robertson, Balazs Acs, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 27, 2025
Histological Grade Has Clinical Validity in Neoadjuvant-Treated Breast Cancer: A Multicenter StudySanna Steen, Constance Boissin, Mattias Rantalainen, et al.
Biomolecules|November 27, 2021
Independent Clinical Validation of the Automated Ki67 Scoring Guideline from the International Ki67 in Breast Cancer Working GroupCeren Boyaci, Wenwen Sun, Stephanie Robertson, et al.
Current Cancer Drug Targets|October 11, 2015
Current State of ERG as Biomarker in Prostatic AdenocarcinomaBalazs Acs, Tibor Szarvas, Nora Szekely, et al.
Breast (Edinburgh, Scotland)|June 13, 2026
A nationwide population-based study on the incidence and prognosis of HER2-positive breast cancer eligible for adjuvant pertuzumab in the modern era of neoadjuvant therapyAntonis Valachis, Xingrong Liu, Balazs Acs, et al.
The Lancet Regional Health. Europe|May 15, 2024
Real-world overall survival and characteristics of patients with ER-zero and ER-low HER2-negative breast cancer treated as triple-negative breast cancer: a Swedish population-based cohort studyBalazs Acs, Johan Hartman, Demet Sönmez, et al.
Cancer Medicine|January 28, 2026
Prognosis of Metaplastic Breast Cancer: A Population-Based Matched Cohort StudyMarie Bergman, Aglaia Schiza, Ceren Boyaci, et al.
The British Journal of Surgery|February 23, 2024
Immune cell infiltrate in ductal carcinoma in situ and the risk of dying from breast cancer: case-control studyGunilla Rask, Charlotta Wadsten, Balazs Acs, et al.
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
The Journal of Pathology|August 30, 2019
Next generation pathology: artificial intelligence enhances histopathology practiceBalazs Acs, Johan Hartman
Breast Cancer Research and Treatment|June 24, 2020
Prognostic potential of automated Ki67 evaluation in breast cancer: different hot spot definitions versus true global scoreStephanie Robertson, Balazs Acs, Michael Lippert, et al.
Heliyon|July 18, 2024
Ensemble-based deep learning improves detection of invasive breast cancer in routine histopathology imagesLeslie Solorzano, Stephanie Robertson, Balazs Acs, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 27, 2025
Histological Grade Has Clinical Validity in Neoadjuvant-Treated Breast Cancer: A Multicenter StudySanna Steen, Constance Boissin, Mattias Rantalainen, et al.
Biomolecules|November 27, 2021
Independent Clinical Validation of the Automated Ki67 Scoring Guideline from the International Ki67 in Breast Cancer Working GroupCeren Boyaci, Wenwen Sun, Stephanie Robertson, et al.
Current Cancer Drug Targets|October 11, 2015
Current State of ERG as Biomarker in Prostatic AdenocarcinomaBalazs Acs, Tibor Szarvas, Nora Szekely, et al.
Breast (Edinburgh, Scotland)|June 13, 2026
A nationwide population-based study on the incidence and prognosis of HER2-positive breast cancer eligible for adjuvant pertuzumab in the modern era of neoadjuvant therapyAntonis Valachis, Xingrong Liu, Balazs Acs, et al.
The Lancet Regional Health. Europe|May 15, 2024
Real-world overall survival and characteristics of patients with ER-zero and ER-low HER2-negative breast cancer treated as triple-negative breast cancer: a Swedish population-based cohort studyBalazs Acs, Johan Hartman, Demet Sönmez, et al.
Cancer Medicine|January 28, 2026
Prognosis of Metaplastic Breast Cancer: A Population-Based Matched Cohort StudyMarie Bergman, Aglaia Schiza, Ceren Boyaci, et al.
The British Journal of Surgery|February 23, 2024
Immune cell infiltrate in ductal carcinoma in situ and the risk of dying from breast cancer: case-control studyGunilla Rask, Charlotta Wadsten, Balazs Acs, et al.
Pageof 6